Penn Medicine experts will be speaking and presenting data on the latest advances in cancer research and treatment at the American Association for Cancer Research’s 2014 Annual Meeting from April 5th through April 9th in San Diego. The program covers every aspect of cancer – from molecular biology, translational and clinical studies, epidemiology, and prevention to survivorship and patient advocacy.
Experts from Penn's Abramson Cancer Center are available to comment on a wide range of cancer research topics. To arrange interviews, please contact Steve Graff at firstname.lastname@example.org or 215-301-5221. Follow us on Twitter at @PennMedNews.
Watch this space for a news release as embargoes lift during the meeting.
Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine and director of Translational Research at the Abramson Cancer Center, will be delivering a plenary talk titled “Engineering T cells for cancer: CARs in the clinic” on Monday, April 7 at 8:15 am PST. An expert in gene therapy and immunotherapeutic approaches to cancer treatment, Dr. June leads the team that published research showing sustained remissions among both adult and pediatric patients with advanced leukemias who were treated with genetically engineered versions of their own T cells. His team is developing strategies to expand this personalized approach into ovarian and pancreatic cancers and mesothelioma.
Peter C. Nowell, MD, the Gaylord P. and Mary Louise Harnwell professor emeritus in the Department of Pathology and Laboratory Medicine, will be formally inducted into the 2014 class of elected fellows of the AACR Academy on Friday, April 4.
M. Celeste Simon, PhD, a professor in the Department of Cell and Development Biology and scientific director and investigator at the Abramson Family Cancer Research Institute, has been elected to the AACR Board of Directors, and will assume her role at the start of the meeting on April 5.
Department of Communications
For Patients and the General Public: